Latest CRISPR Therapeutics News & Updates

See the latest news and media coverage for CRISPR Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

CRISPR Therapeutics

Biotechnology company developing gene-based medicines

crisprtx.com

Headquarters: Boston, United States
Founded year: 2013
Company type: Public company
Number of employees: 300–500
Industry: Biotechnology & Medical Research

Last updated October 19

Latest news about CRISPR Therapeutics

In short: CRISPR Therapeutics posted strong 2026 results, expanded CASGEVY to young children, and showed durable CTX310 cholesterol cuts.

Company announcements

October 19 CRISPR Therapeutics

CRISPR Therapeutics appoints A.J. Silver as CFO

Raju Prasad steps down to pursue external opportunities while A.J. Silver takes over the financial leadership role effective immediately.

August 3 CRISPR Therapeutics

CRISPR Therapeutics reports second quarter 2026 financial results

CASGEVY revenue grew 151% year-over-year, FDA approved it for children as young as 2, and Phase 1 trials for CTX340 and CTX460 were initiated.

July 2 CRISPR Therapeutics

CRISPR Therapeutics expands FDA approval for young children

It is the first gene-edited therapy approved for children this young, covering both sickle cell disease and beta thalassemia.

May 4 CRISPR Therapeutics

CRISPR Therapeutics reported Q1 2026 financial results and business update

Revenue included $43M from CASGEVY, cash increased to $2.44B, and development milestones advanced across pipeline.

Media coverage

October 2 BiopharmaWatch

CTX310 Data Presentation at AHA 2026 - CRSP | BioPharmaWatch

CRISPR Therapeutics will present late-breaking data on CTX310 at AHA 2026, targeting severe hypertriglyceridemia.

September 26 ScienceDaily

One CRISPR treatment cut "bad" cholesterol in half for a full year

A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were...

September 23 Seeking Alpha

Gene editing stocks fall after Anthropic's CRISPR-like discovery

Gene editing companies traded lower on Wednesday after Anthropic (ANTHRO) announced that its AI model Claude has "autonomously discovered" a new enzyme system similar to...

September 14 Seeking Alpha

CRISPR Therapeutics set to snap losing streak

The stock rebounds 3% after six consecutive losses, while analysts remain bullish on the biotech company.

Never miss news about CRISPR Therapeutics

Track CRISPR Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

CRISPR Therapeutics competitors & trending companies

Browse news for competitors to CRISPR Therapeutics and other trending companies.